Novartis AG (ADR)  

(Public, NYSE:NVS)   Watch this stock  
Find more results for nvs
77.10
-3.57 (-4.43%)
Jun 24 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 77.08 - 79.36
52 week 69.89 - 106.84
Open 77.37
Vol / Avg. 3.17M/1.96M
Mkt cap 198.54B
P/E 27.81
Div/yield 2.72/3.53
EPS 2.77
Shares 2.32B
Beta 0.62
Inst. own 10%
Sep 22, 2016
Novartis AG at Sanford C Bernstein Pan European Conference Add to calendar
Sep 15, 2016
Novartis AG at Bank of America Merrill Lynch Healthcare Conference Add to calendar
Jul 19, 2016
Q2 2016 Novartis AG Earnings Release Add to calendar
Jun 23, 2016
Novartis AG at JPMorgan European Healthcare Conference
Jun 22, 2016
Novartis AG at Citi European Healthcare Conference
Jun 8, 2016
Novartis AG at Goldman Sachs European Financials Conference
May 25, 2016
Novartis AG Meet Novartis Management
Apr 21, 2016
Q1 2016 Novartis AG Earnings Call
Apr 21, 2016
Q1 2016 Novartis AG Earnings Release
Mar 31, 2016
Novartis AG Updated 2015 Segment Financials Reflecting New Division Structure Corporate Call
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin 17.03% 13.96%
Operating margin 20.33% 17.56%
EBITD margin - 31.53%
Return on average assets 6.11% 5.47%
Return on average equity 10.84% 9.49%
Employees 118,000 -
CDP Score - 98 B

Address

Lichtstrasse 35
BASEL, 4056
Switzerland
+41-61-3241111 (Phone)
+41-61-3247826 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Novartis AG is a holding company. The Company specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. Its portfolio includes medicines, eye care and generic pharmaceuticals. The Company's segments include Pharmaceuticals, Alcon and Sandoz. Its Pharmaceuticals segment is engaged in researching, developing, manufacturing, distributing and selling patented prescription medicines in the therapeutic areas, such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience and established medicines. Its Alcon segment is engaged in developing, manufacturing and selling eye care products across the world. Its Sandoz segment is engaged in developing, manufacturing and marketing generic pharmaceutical products, follow-on biopharmaceutical products known as biosimilars and drug substances that are not protected by valid and enforceable third-party patents.

Officers and directors

Joerg Reinhardt Ph.D. Chairman of the Board of Directors
Age: 60
Bio & Compensation  - Reuters
Joseph Jimenez Chief Executive Officer, Member of the Executive Committee
Age: 56
Bio & Compensation  - Reuters
Harry Kirsch Chief Financial Officer, Member of the Executive Committee
Age: 50
Bio & Compensation  - Reuters
Felix R. Ehrat Ph.D. Group General Counsel, Member of the Executive Committee
Age: 59
Bio & Compensation  - Reuters
Steven Baert Head of Human Resources and Member of the Executive Committee
Age: 41
Bio & Compensation  - Reuters
David R. Epstein Member of the Executive Committee, Division Head, Pharmaceuticals
Age: 54
Bio & Compensation  - Reuters
Mark C. Fishman M.D. Member of the Executive Committee and President of Novartis Institute for BioMedical Research (NIBR)
Age: 64
Bio & Compensation  - Reuters
Richard Francis Member of the Executive Committee and Division Head, Sandoz
Age: 47
Bio & Compensation  - Reuters
Jeffrey George Member of the Executive Committee and Division Head, Alcon.
Age: 42
Bio & Compensation  - Reuters
Andre Wyss Member of the Executive Committee, Global Head, Novartis Business Services and Country President for Switzerland
Age: 48
Bio & Compensation  - Reuters